<DOC>
	<DOCNO>NCT02961998</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) common fatal malignant tumor , although popularity health examination , patient diagnose HCC advance stage far . Sorafenib currently recognize worldwide effective treatment advance HCC . However , sorafenib need long-term medication , bring series side effect , include , hand , foot comprehensive syndrome ( Hand-foot syndrome , HFS ) limbs swell , rash , peeling , pain.Occurrence rate HFS 21 % -51 % , seriously affect patient 's quality life.Besides , side effect appear dose-related.When severe HFS happen , sorafenib need reduce dosage discontinue administration , could seriously affect patient 's survival . Therefore , investigator design prospective randomize control study explore preventive effect celecoxib sorafenib relate HFS , influence quality life patient , also synergistic anti-tumor effect celecoxib combination sorafenib HCC . This study explore horizon improve treatment sorafenib patient advance HCC , quality life tumor control .</brief_summary>
	<brief_title>Preventive Effect Celecoxib Sorafenib-related Hand Foot Syndrome , Single Center , Randomized Controlled Clinical Trail</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1.Diagnosed HCC accord Primary liver cancer diagnosis treatment practice publish Ministry Health 2011 China 2.A Karnofsky Performance Status ( KPS ) score ≥70 point 3.Age 18 70 year 4.ChildPugh classA B ( class B patient score great 7 point ) . In addition , baseline laboratory test meet follow criterion : white blood cell ( WBCs ) ≥1.5 × 109/L , platelet ≥50 × 109/L , hemoglobin ≥80 g/L , serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2 x upper limit normal ( ULN ) , serum creatinine ≤ 1.5 x ULN , international normalize ratio ( INR ) &lt; 1.5 prothrombin time &lt; ULN + 4 second , albumin ≥30 g/L , total bilirubin ≤34mmol/L 5.Patients advanced hepatocellular carcinoma fail firstline therapy surgery，radiofrequency ablation 1.Pugh ChildPugh Grade C , massive ascites history hepatic encephalopathy , previous history gastrointestinal bleeding 2.Poor general condition cachexia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>sorafenib</keyword>
	<keyword>celecoxib</keyword>
</DOC>